{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.0235","value":"110.138"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"title":"Day 1 - AUC0-24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.5203","value":"134.033"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"Day 8 - AUC0-24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.3453","value":"132.019"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Day 1 - AUC0-48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.2278","value":"159.750"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Day 8 - AUC0-48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.9389","value":"134.828"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"title":"Day 1- AUC (0-inf)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"65.0664","value":"162.673"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Day 8 - AUC (0-inf)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"139"}],"units":"Participants"}],"description":"AUC is defined as the area under concentration-time curve as a measure of drug exposure. The area under the plasma concentration-time curve from time zero to 24 hours. The area under the plasma concentration-time curve from time zero to 48 hours. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Panobinostat 20 mg/day capsule orally, OD on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5). The treatment duration was not fixed. Participants continued treatment until disease progression or unacceptable toxicity occurred.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"The analysis was performed in PAS population, defined as all participants who provide at least one post-dose PK plasma sample. Here, number of participants analyzed refer to the number of participants evaluable for this outcome at specified time point.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 1-2, and 3-4 hours post dose on Day 1 and Day 8","title":"Area Under the Plasma Concentration AUC0-24, AUC0-48 and AUC 0-infinity of Panobinostat","type":"SECONDARY","unitOfMeasure":"ng*hr/ml"}